GX-I7 T-cell immunity Amplifier by interleukin-7(IL-7) fused to hyFc

GX-I7 (Efineptakin alfa)

A recombinant human interleukin-7(IL-7) fused to hyFc

Disease Indication

Radiation and chemotherapy-related lymphopenia, solid tumors including TNBC, GBM, etc., and lymphopenia due to infectious diseases

Development Stage

Genexine and our partners are currently conducting Phase 1 & Phase 2 clinical trials of GX-I7 as a monotherapy or in combination with other anti-cancer treatment, including checkpoint inhibitors, in solid tumors, lymphopenia and infectious disease.

Development Stage
Field Type Combination Indication Development Phase Sponsor Partner
Preclinical Phase 1 Phase 2 Phase 3

Phase 1b/2, KEYNOTE-899

COM Avastin Recurrent GBM
Preclinical Phase 1 Phase 2 Phase 3

Phase 2

COM GX-188E/Opdivo Recurrent HNSCC (HPV16)
Investigator-Initiated Trial (IIT)
Preclinical Phase 1 Phase 2 Phase 3

Phase 2a


GX-I7 (INN: efineptakin alfa) is a recombinant protein developed by the fusion of human recombinant hybrid Fc (hyFc) with a human T cell growth factor, IL-7 (Interleukin-7) to optimize the function of IL-7.
IL-7 is a T cell growth factor mainly involved in differentiation, proliferation, and survival of naïve T cells and memory T cells which are associated with recognition and targeting of antigens among a variety of T cells, but it does not induce proliferation of regulatory T cells which suppress effector T cells. In addition, IL-7 is one of the cytokines with low risk of severe side effects such as cytokine storms since it maintains T cell homeostasis through IL-7 receptor (CD127), thereby having the advantage of safe use. It can induce not only a quantitative increase in the level of T cells but also anti-tumour effects involving targeting the cancer cells and penetration into cancer cells/cancer tissues.


Fusion of engineered IL-7 to the hyFc platform composed of IgG4 and IgD.


Acts on IL-7 receptors, increasing CD4 and CD8 T cells (Naive & memory subtype)



GX-I7 is a T-cell amplifier that increases the number of T cells and enhances cancer immunity and potentially provide greater therapeutic benefits to patients.


GX-I7+Keytruda (mTNBC Patients)

GX-I7+Keytruda (mTNBC Patients)
≥ 2L GX-I7
Ph1b/2, combo with Pembro (N=33, Ph2)
NCT No. NCT03752723
Prior CTx. 1st ~ 3rd line
ORR Ph2 21.2%
CPS>10 60% (6/10)
DCR 33.3 %


  1. 1Crucial Roles of Interleukin-7 in the Development of T Follicular Helper Cells and in the Induction of Humora l Immunity. (J Virol. 2014)
  2. 22019 AACR Poster Publication
  3. 32020 ASCO Poster Publication (2020-05)
  4. 42020 SITC Poster Publication (2020-11)
  5. 5Compassionate Use of the human recombinant IL-7 for restoring lymphopenia as a salvage treatment in pat ients with recurrent glioblastoma (KAI International Meeting 2020 Poster Publication)
  6. 6Recombinant human IL-7-hyFc for Recurrent GBM (2022.01, MedRxiv Publication)
  7. 7Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma (Cancer Immunity, 2022)